CNS, Lung, and Lymph Node Involvement in Gaucher Disease Type 3 After 11 Years of Therapy: Clinical, Histopathologic, and Biochemical Findings

Overview

Journal Mol Genet Metab

Specialty Endocrinology

Date 2014 Sep 16

PMID 25219293

Citations 36

Authors

Thomas A Burrow

Ying Sun

Carlos E Prada

Laurie Bailey

Wujuan Zhang

Amanda Brewer

Steve W Wu

Kenneth D R Setchell

David Witte

Mitchell B Cohen

Gregory A Grabowski

Affiliations

Soon will be listed here.

Abstract

A Caucasian male with Gaucher disease type 3, treated with continuous enzyme therapy (ET) for 11 years, experienced progressive mesenteric and retroperitoneal lymphadenopathy, lung disease, and neurological involvement leading to death at an age of 12.5 years. Autopsy showed significant pathology of the brain, lymph nodes, and lungs. Liver and spleen glucosylceramide (GluCer) and glucosylsphingosine (GluS) levels were nearly normal and storage cells were cleared. Clusters of macrophages and very elevated GluCer and GluS levels were in the lungs, and brain parenchymal and perivascular regions. Compared to normal brain GluCer (GC 18:0), GluCer species with long fatty acid acyl chains were increased in the patient's brain. This profile was similar to that in the patient's lungs, suggesting that these lipids were present in brain perivascular macrophages. In the patient's brain, generalized astrogliosis, and enhanced LC3, ubiquitin, and Tau signals were identified in the regions surrounding macrophage clusters, indicating proinflammation, altered autophagy, and neurodegeneration. These findings highlight the altered phenotypes resulting from increased longevity due to ET, as well as those in poorly accessible compartments of brain and lung, which manifested progressive disease involvement despite ET.

Citing Articles

Intrinsic link between PGRN and Gba1 D409V mutation dosage in potentiating Gaucher disease.

Lin Y, Zhao X, Liou B, Fannin V, Zhang W, Setchell K Hum Mol Genet. 2024; 33(20):1771-1788.

PMID: 39101473 PMC: 11458007. DOI: 10.1093/hmg/ddae113.

A case of gaucher disease with a rare complication of gaucheroma and protein-losing enteropathy.

Zhang T, Zhang X, Zhang N, Yan J, Wang L, Yan W Mol Genet Metab Rep. 2024; 39:101075.

PMID: 38571878 PMC: 10988120. DOI: 10.1016/j.ymgmr.2024.101075.

Reduced progranulin increases tau and α-synuclein inclusions and alters mouse tauopathy phenotypes via glucocerebrosidase.

Takahashi H, Bhagwagar S, Nies S, Ye H, Han X, Chiasseu M Nat Commun. 2024; 15(1):1434.

PMID: 38365772 PMC: 10873339. DOI: 10.1038/s41467-024-45692-3.

iPSC-derived neural precursor cells engineering recovers acid β-glucosidase deficiency and diminishes α-synuclein and neuropathology.

Peng Y, Liou B, Lin Y, Mayhew C, Fleming S, Sun Y Mol Ther Methods Clin Dev. 2023; 29:185-201.

PMID: 37063480 PMC: 10102010. DOI: 10.1016/j.omtm.2023.03.007.

PGRN deficiency exacerbates, whereas a brain penetrant PGRN derivative protects, mutation-associated pathologies and diseases.

Zhao X, Lin Y, Liou B, Fu W, Jian J, Fannie V Proc Natl Acad Sci U S A. 2022; 120(1):e2210442120.

PMID: 36574647 PMC: 9910439. DOI: 10.1073/pnas.2210442120.

References

Bell R, Zlokovic B . Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009; 118(1):103-13. PMC: 2853006. DOI: 10.1007/s00401-009-0522-3. View

Nilsson O, Svennerholm L . Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem. 1982; 39(3):709-18. DOI: 10.1111/j.1471-4159.1982.tb07950.x. View

Cullen V, Sardi S, Ng J, Xu Y, Sun Y, Tomlinson J . Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol. 2011; 69(6):940-53. DOI: 10.1002/ana.22400. View

Sun Y, Zamzow M, Ran H, Zhang W, Quinn B, Barnes S . Tissue-specific effects of saposin A and saposin B on glycosphingolipid degradation in mutant mice. Hum Mol Genet. 2013; 22(12):2435-50. PMC: 3708521. DOI: 10.1093/hmg/ddt096. View

Sato Y, Beutler E . Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. J Clin Invest. 1993; 91(5):1909-17. PMC: 288185. DOI: 10.1172/JCI116409. View

Burudi E, Regnier-Vigouroux A . Regional and cellular expression of the mannose receptor in the post-natal developing mouse brain. Cell Tissue Res. 2001; 303(3):307-17. DOI: 10.1007/s004410000311. View

Marshall J, McEachern K, Chuang W, Hutto E, Siegel C, Shayman J . Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy. J Inherit Metab Dis. 2010; 33(3):281-9. PMC: 3683842. DOI: 10.1007/s10545-010-9072-z. View

Zhao H, Bailey L, Elsas 2nd L, Grinzaid K, Grabowski G . Gaucher disease: in vivo evidence for allele dose leading to neuronopathic and nonneuronopathic phenotypes. Am J Med Genet A. 2002; 116A(1):52-6. DOI: 10.1002/ajmg.a.10029. View

Barton N, Brady R, Dambrosia J, Di Bisceglie A, Doppelt S, Hill S . Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991; 324(21):1464-70. DOI: 10.1056/NEJM199105233242104. View

10.

Boven L, van Meurs M, Boot R, Mehta A, Boon L, Aerts J . Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004; 122(3):359-69. DOI: 10.1309/BG5V-A8JR-DQH1-M7HN. View

11.

Hickey W, Kimura H . Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988; 239(4837):290-2. DOI: 10.1126/science.3276004. View

12.

Nilsson O, Grabowski G, Ludman M, Desnick R, Svennerholm L . Glycosphingolipid studies of visceral tissues and brain from type 1 Gaucher disease variants. Clin Genet. 1985; 27(5):443-50. DOI: 10.1111/j.1399-0004.1985.tb00229.x. View

13.

Wong K, Sidransky E, Verma A, Mixon T, Sandberg G, Wakefield L . Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab. 2004; 82(3):192-207. DOI: 10.1016/j.ymgme.2004.04.011. View

14.

Burrow T, Cohen M, Bokulic R, Deutsch G, Choudhary A, Falcone Jr R . Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapy. J Pediatr. 2007; 150(2):202-6. DOI: 10.1016/j.jpeds.2006.10.062. View

15.

Conradi N, SOURANDER P, Nilsson O, Svennerholm L, Erikson A . Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies. Acta Neuropathol. 1984; 65(2):99-109. DOI: 10.1007/BF00690463. View

16.

Achord D, Brot F, Bell C, Sly W . Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell. 1978; 15(1):269-78. DOI: 10.1016/0092-8674(78)90102-2. View

17.

Furbish F, Steer C, Krett N, Barranger J . Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta. 1981; 673(4):425-34. DOI: 10.1016/0304-4165(81)90474-8. View

18.

Rudel L, Morris M . Determination of cholesterol using o-phthalaldehyde. J Lipid Res. 1973; 14(3):364-6. View

19.

Mazzulli J, Xu Y, Sun Y, Knight A, McLean P, Caldwell G . Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell. 2011; 146(1):37-52. PMC: 3132082. DOI: 10.1016/j.cell.2011.06.001. View

20.

Baetas-da-Cruz W, Alves L, Pessolani M, Barbosa H, Regnier-Vigouroux A, Corte-Real S . Schwann cells express the macrophage mannose receptor and MHC class II. Do they have a role in antigen presentation?. J Peripher Nerv Syst. 2009; 14(2):84-92. DOI: 10.1111/j.1529-8027.2009.00217.x. View